1	Complementary non-sputum diagnostic testing using oral swabs and urine LAM
2	testing for TB in people with HIV
3	
4	Running title: Oral swabs & urine LAM for TB diagnosis
5	
6	Adrienne E. Shapiro ^{1,2} , Alaina M. Olson ³ , Lara Kidoguchi ¹ , Xin Niu ⁴ , Zinhle Ngcobo ⁵ , Zanele P.
7	Magcaba ⁵ , Mduduzi W. Ngwane ⁵ , Grant R. Whitman ³ , Kris M. Weigel ³ , Rachel C. Wood ³ , Doug
8	P.K. Wilson ^{5,6} , Paul K. Drain ^{1,2} , Gerard A. Cangelosi ^{1,3,4*}
9	
10	¹ Department of Global Health, University of Washington, Seattle, WA, USA; ² Department of
11	Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA,
12	USA; ³ Department of Environmental and Occupational Health Sciences, University of
13	Washington, Seattle, WA, USA; ⁴ Department of Epidemiology, University of Washington, Seattle,
14	WA, USA; 5 Umkhuseli Research and Innovation Management, Pietermaritzburg, South Africa;
15	⁶ University of KwaZulu-Natal, Pietermaritzburg, South Africa
16	
17	*Corresponding author: Gerard Cangelosi, Dept. of Environmental and Occupational Health
18	Sciences, Box 351618, University of Washington, Seattle, WA 98195. Email: gcang@uw.edu
19	
20	Key words: tuberculosis, oral swabs, diagnostic, urine, non-sputum, lipoarabinomannan (LAM),
21	OSA, tongue swabs.

22

23 Abstract

24	Testing for mycobacterial lipoarabinomannan (LAM) in urine is a practical but insensitive
25	alternative to sputum testing to diagnose tuberculosis (TB) in people with HIV (PWH). We
26	evaluated urine LAM testing conducted in parallel with tests for Mycobacterium tuberculosis
27	DNA in oral swabs. In a cohort of 131 South Africans (92% with HIV), combined urine LAM and
28	oral swab testing was significantly more sensitive than either sample tested alone (57% vs. 35%
29	and 39%, respectively), and 97% specific, compared to reference sputum testing (TB culture
30	and Xpert Ultra). Complementary non-sputum sample testing increased sensitivity of TB
31	diagnosis, without sacrificing specificity.
32	

33

35 Background

36	Tuberculosis disease (TB), caused by Mycobacterium tuberculosis (MTB), remains a
37	major cause of illness and death in PWH [1]. The standard sample for TB diagnosis is sputum,
38	which can be difficult for PWH to produce and insensitive in some patients. The availability of
39	noninvasive alternatives to sputum testing would substantially improve TB care for PWH [2, 3].
40	Immunoassays for mycobacterial lipoarabinomannan (LAM) in urine are potential
41	alternatives to sputum testing. However, the single WHO-approved urine LAM test (by
42	Alere/Abbott) lacks sensitivity. Although next-generation urine LAM tests are in development or
43	evaluation, even best-performing tests of the LAM analyte alone may not be optimally sensitive
44	to detect TB disease in PWH [4, 5].
45	In search of an alternative non-sputum sample type, we and others have shown that
46	MTB DNA can be detected by oral swab analysis (OSA) [6-14]. In OSA, the dorsum of the
47	tongue is brushed with a sterile swab, and the collected material is tested for MTB DNA. This
48	non-invasive, non-sputum sample collection approach can be applied to any patient, in any
49	setting, including tertiary hospital, outpatient clinic, remote health point, or home and community
50	settings.
51	Despite their promise, to date neither OSA nor urine LAM testing has proven to be
52	sensitive enough to detect all TB in PWH. We hypothesize that sensitivity is limited for different
53	reasons in the two methods. For example, pulmonary disease may be required to deposit
54	enough MTB in the mouth for detection by OSA, whereas a very high total mycobacterial burden,
55	including extrapulmonary disease, may be required for transrenal passage of MTB glycolipids
56	into urine. Therefore, a parallel approach using both methods may detect more TB cases in
57	PWH than either method alone. The current study was conducted to assess the

59

60 Methods

61 Participant enrollment: South African adults (age ≥16 years) with HIV (regardless of 62 symptoms), or adults with TB symptoms or a positive sputum Xpert Ultra TB test, were 63 consecutively enrolled into the prospective PROVE-TB cohort at Edendale Hospital and 64 affiliated clinics in Pietermaritzburg, South Africa between October 2019 and February 2021. 65 Persons who had received TB treatment for more than 24 hours were excluded. Clinical, 66 laboratory, and demographic data were collected from participants and clinical charts. Sputum, 67 urine, tongue swab, and blood samples were collected at bedside and transported to the on-site 68 laboratory for processing and analysis. Study data were collected and managed using REDCap 69 electronic data capture tools hosted at the Institute of Translational Health Sciences. All 70 participants provided written informed consent. This study was approved by the ethical 71 committees of the University of KwaZulu-Natal (BREC #BE475/18) and the University of 72 Washington.

73 Sample collection and analysis. Expectorated sputum samples were tested with Cepheid 74 GeneXpert MTB/RIF Ultra (Xpert Ultra) and mycobacterial culture (National Health Laboratory 75 System, South Africa). A TB case was defined as a participant with either a positive sputum 76 Xpert Ultra or a positive sputum TB culture result (reference testing). Spontaneously passed 77 urine samples were tested for the presence of LAM using the Alere DETERMINE LAM Ag 78 lateral-flow assay. A result of 1+ or higher according to the manufacturer's visual read-out card 79 was considered positive. Two tongue dorsum swabs (Copan FLOQSwabs) were collected into 80 separate tubes as described previously [7, 8]. Swabs in 0.5 mL TE buffer were stored frozen at -81 80 °C and transported to the Cangelosi Lab for blinded analysis. Thawed samples were 82 manually processed (Qiagen), concentrated by ethanol precipitation, and tested by IS6110-83 targeted qPCR. Swab analysis methods were as described previously [7, 8] with the following

84 modifications. Post-boil samples were eluted from the swab head then split, 250 μ L reserve and 85 250 μ L for immediate processing by volume-scaled-lysis (300 μ L each of Qiagen Buffer AL and 86 100% ethanol). The qPCR protocol used New England BioLabs® Inc Luna® Universal Probe 87 qPCR Master Mix, and the ethanol-precipitated samples were rehydrated in 5 μ L TE buffer prior 88 to master mix addition. Cq values were recorded and results were calculated using two Cq 89 thresholds (38 as described previously [7, 8], and a more stringent value of 32).

90 In addition, a subset of reserved or duplicate oral swab samples (N=18) were tested 91 using by either of two methods. In one method, previously boiled, reserved (200 µL) half 92 samples were thawed and received 2.2 mL TE buffer. The samples were shaken on a lab 93 vortexer (GENIE® SI-0236 Vortex-Genie 2 Mixer, 120V) on setting 10 for 10-15 seconds, then 94 allowed to sit at ambient temperature for 5 minutes and then shaken for an additional 10-15 95 seconds, before allowing them sit for additional 10 minutes at ambient temperature. The entire 96 recoverable sample volume was transferred into the sample reservoir of the Xpert Ultra 97 cartridge for analysis. Samples were recorded as positive for MTB if GeneXpert software 98 returned any positive result. Some samples were run by an alternative method that did not use 99 heat. These 0.5-mL samples were thawed at ambient temperature for 30 min, then 100 supplemented with 0.3 mL TE and 1.6 mL of Cepheid Sample Reagent (SR). The samples were 101 vortexed for 10-15 seconds, and incubated for 5 minutes before vortexing for an additional 10-102 15 seconds. The samples were further incubated for additional 10 minutes before the entire 103 sample volume was transferred to the cartridges.

Sensitivities and specificities of index methods (swabs, urine LAM, and parallel testing)
were calculated relative to the reference method (positive sputum Xpert Ultra or positive sputum
culture).

107

109 Results

We enrolled 131 participants (45% female, median age 36 years) who provided all
sample types for index and reference testing. 120 (92%) participants had HIV. 64 (49%) were
TB cases by reference testing (Figure 1).

Relative to the sputum reference standard, OSA using manual qPCR conducted on a single swab, with a Cq cutoff of 38, was significantly more sensitive than urine LAM (respectively, 42/64 [67%] vs. 22/63 [35%]). However, OSA was less specific than urine LAM (respectively, 52/67 [78%] vs. 67/67 [100%]). When a more stringent Cq cutoff of 32 was applied to define a positive OSA result, OSA and urine LAM performed similarly (respectively,

118 25/64 [39%] vs. 22/63 [35%] sensitive, and 65/67 [97%] vs. 67/67 [100%] specific) **(Table 1).**

When evaluating parallel (combination) non-sputum testing, a positive index test was defined as being <u>either</u> urine LAM-positive <u>or</u> OSA-positive. With parallel testing, sensitivity improved to 36/63 [57%], significantly better than urine LAM alone (p=0.006) or OSA alone (p=0.021). Of the 36 participants who were true positive by non-sputum methods, 11 were positive by both methods while 25 were positive by only one or the other (14 by OSA and 11 by urine LAM; **Figure 1**). Specificity of the combined method remained high at 65/67 (97%).

The manual qPCR method used in Table 1 performed well in past OSA studies [7, 8, 14] but is impractical for routine diagnostic use. Therefore, as a secondary analysis we used the semi-automated Cepheid GeneXpert MTB/RIF Ultra platform to test a subset of 18 frozen swab samples from the current study (11 true positives with strong qPCR signals by OSA, 5 true negatives by OSA, and the 2 false positives by OSA). Xpert Ultra detected 10 of 11 true positives by OSA (the 11th sample had an invalid Xpert Ultra result). It correctly excluded all 5 true negatives by OSA. It also correctly excluded the 2 false positives by OSA (**Table S1**).

133 Discussion

134	Many PWH struggle to produce sputum (sputum-scarce) and/or have low MTB cell
135	counts in sputum (paucibacillary) [2, 3]. This study tested the hypothesis that parallel testing of
136	two different non-sputum samples can deliver complementary, not redundant diagnostic
137	information, and thereby serve as an alternative to sputum testing for at least some patients.
138	Recent years have seen advancements in urine LAM testing for sputum-scarce or
139	paucibacillary patients. LAM is an MTB cell wall glycolipid that can pass transrenally into urine.
140	In some patients, most notably PWH with low CD4 counts, LAM is found in the urine in sufficient
141	quantities to enable rapid detection by using lateral flow tests such as the Alere Determine [™] TB
142	LAM Ag. However, the sensitivity of urine LAM tests remains suboptimal [4, 5].
143	We hypothesized that OSA can improve TB diagnosis in paucibacillary and sputum-
144	scarce patients when used in combination with urine LAM testing. The physiological bases for
145	urine LAM testing (transrenal passage of a mycobacterial glycolipid) and OSA (deposition of
146	MTB cells and/or DNA on the tongue dorsum during cough, exhalation, or spontaneous sputum
147	production) are likely to differ from each other. Urine LAM may work best in cases that are at
148	least partially extrapulmonary, while OSA may be best in pulmonary TB. The strengths and
149	limitations of the two methods may therefore complement each other.
150	The results were consistent with this hypothesis. When the more stringent Cq cutoff of
151	32 was applied, a diagnostic criterion of positivity in either urine LAM or OSA was significantly

more sensitive than either method alone. Specificity was acceptable at 97% and was the

153 minimum of the individual test specificities, but not lower in combination.

154 This study focused on the biological question of complementarity. Limitations associated 155 with implementation were only partially addressed. While swab sample collection has minimal 156 resource requirements, the manual qPCR method for OSA requires laboratory facilities, 157 specialized equipment and skilled technical operators, so is not practical for routine clinical

Iaboratory use in its current form. However, analysis of a subset of 18 samples with the near point-of-care Xpert Ultra platform suggested that similar results can be obtained with automated tests (with the caveat that the true-positive samples within the subset were strongly positive by manual qPCR). Therefore, this strategy can in theory be applied in any setting with access to both Alere Determine[™] TB LAM AG and Xpert Ultra. Other automated amplification platforms intended for near-point-of-care or point-of-care use are also in development and have the potential to be configured for TB OSA.

165 Another implementation concern is the requirement for two laboratory tests per patient. 166 In context, the same limitation often applies to the current sputum-dependent strategies 167 (paucibacillary and sputum-scarce patients often require multiple sampling and testing attempts 168 to confirm TB). Urine and tongue swabs are easier and safer to collect than sputum samples in 169 most settings. To conserve resources, the two specimens could be collected simultaneously 170 and then tested in a staged reflex algorithm. By design, oral swabs are easy and inexpensive to 171 collect from any patient, in any setting. Swabs can therefore be collected and stored 172 concurrently with the collection of all urine samples. If a patient's urine sample is positive for 173 LAM, then that is diagnostic for TB and a swab test is not needed. If the urine LAM test is 174 negative, then the swab can be tested to avoid having to recall the patient for sputum induction. 175 In conclusion, our results indicate that tongue swabs and urine can serve as 176 complementary non-sputum samples for improved diagnosis of TB in PWH. With further 177 optimization to improve sensitivity, this approach may be considered as a fully non-sputum 178 strategy for detecting TB in sputum-scarce patients. 179 180

181

183 Footnote page

184 Conflict of interest statement: The authors have no conflicts of interest to declare.

185

- 186 This work was supported by the Bill and Melinda Gates Foundation (#INV-004527, OPP
- 187 1213054), by NIH grants R01AI139254 and U54EB027049. REDCap at ITHS is supported by
- the National Center For Advancing Translational Sciences of the National Institutes of Health
- under Award Number UL1 TR002319. AES is supported by NIH (NIAID) K23A140918. We are
- 190 grateful to Cepheid, Inc., for providing research-use-only Xpert Ultra test kits, and to Copan
- 191 Italia for providing swabs.
- 192
- 193 This work was presented in part at virtual TB Science 2021, (Abstract #TBS-LB-2021-02134)


194

195

- 197
- 198

199 Figure 1. Venn diagram showing overlap of the 2 non-sputum tests (tongue swab and urine

- 200 LAM) and the sputum TB reference (Xpert Ultra or TB culture). The number of positive
- 201 participants falling within each category is shown (N=131 participants).
- 202 *One TB ref+/OSA- participant had an invalid LAM result.
- 203



- 221
- 222
- 223
- 224

Table 1. Sensitivity and specificity of non-sputum tests alone or in combination, compared to
 TB reference standard (sputum Xpert Ultra or sputum culture).

227

	Sensitivity	Specificity
Tongue Swab (OSA) Cq<32	25/64 (39%)	65/67 (97%)
Tongue Swab (OSA) Cq<38	42/64 (67%)	52/67 (78%)
Urine LF-LAM	22/63 (35%)	67/67 (100%)
LAM or OSA* $_{Cq<32}$	36/63 (57%)	65/67 (97%)
LAM or OSA* _{Cq<38}	45/63 (71%)	52/67 (78%)

* OSA by manual qPCR using 2 thresholds of positivity: Cq<38 (liberal) and Cq<32 (stringent).

230 Literature cited

- 231
- 232

233 1. World Health Organization. Global Tuberculosis Report 2020.

UNITAID. Tuberculosis diagnostics technology and market landscape - 5th edition.
 World Health Organization. 2017.

3. Fauci, AS, Eisinger RW. Reimagining the Research Approach to Tuberculosis. Am J
Trop Med Hyg. 2018;98(3):650-2.

Shah M, Hanrahan C, Wang ZY, Dendukuri N, Lawn SD, Denkinger CM, et al. Lateral
flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults.
Cochrane Database of Systematic Reviews. 2016;(5).

Broger T, Sossen B, du Toit E, Kerkhoff AD, Schutz C, Ivanova Reipold E, et al. Novel
lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy
study. The Lancet Infectious Diseases. 2019;19(8):852-61.

LaCourse SM, Seko E, Wood R, Bundi W, Ouma GS, Agaya J, et al. Diagnostic
performance of oral swabs for non-sputum based TB diagnosis in a TB/HIV endemic setting.
PLoS One. 2022;17(1):e0262123. Epub 2022/01/14.

Wood RC, Andama A, Hermansky G, Burkot S, Asege L, Job M, et al. Characterization
of oral swab samples for diagnosis of pulmonary tuberculosis. PLOS ONE.

249 2021;16(5):e0251422. doi: 10.1371/journal.pone.0251422.

250 8. Luabeya AK, Wood RC, Shenje J, Filander E, Ontong C, Mabwe S, et al. Noninvasive
251 Detection of Tuberculosis by Oral Swab Analysis. Journal of Clinical Microbiology.
252 2019;57(3):e01847-18.

9. Wood RC, Luabeya AK, Weigel KM, Wilbur AK, Jones-Engel L, Hatherill M, et al.
Detection of Mycobacterium tuberculosis DNA on the oral mucosa of tuberculosis patients.
Scientific Reports. 2015;5:8668.

256 10. Nicol MP, Wood RC, Workman L, Prins M, Whitman C, Ghebrekristos Y, et al.

257 Microbiological diagnosis of pulmonary tuberculosis in children by oral swab polymerase chain 258 reaction. Scientific Reports. 2019;9(1):10789.

11. Valinetz ED, Cangelosi GA. A Look Inside: Oral Sampling for Detection of Non-Oral
 Infectious Diseases. Journal of Clinical Microbiology. 2021;JCM.02360-20.

12. Flores JA, Calderon R, Mesman AW, Soto M, Coit J, Aliaga J, et al. Detection of
Mycobacterium Tuberculosis DNA in Buccal Swab Samples from Children in Lima, Peru. The
Pediatric Infectious Disease Journal. 2020;39(11).

13. Mesman AW, Calderon R, Soto M, Coit J, Aliaga J, Mendoza M, et al. Mycobacterium tuberculosis detection from oral swabs with Xpert MTB/RIF ULTRA: a pilot study. BMC Res

266 Notes. 2019;12(1):349-.

267 14. Song Y, Ma Y, Liu R, Shang Y, Ma L, Huo F, et al. Diagnostic Yield of Oral Swab

268 Testing by TB-LAMP for Diagnosis of Pulmonary Tuberculosis. Infect Drug Resist. 2021;14:89-

- 269 95.
- 270